436 related articles for article (PubMed ID: 35632675)
1. Innate and Adaptive Immune Responses in the Upper Respiratory Tract and the Infectivity of SARS-CoV-2.
Ramasamy R
Viruses; 2022 Apr; 14(5):. PubMed ID: 35632675
[TBL] [Abstract][Full Text] [Related]
2. Perspective of the Relationship between the Susceptibility to Initial SARS-CoV-2 Infectivity and Optimal Nasal Conditioning of Inhaled Air.
Ramasamy R
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360686
[TBL] [Abstract][Full Text] [Related]
3. Innate and adaptive immune responses to SARS-CoV-2 in humans: relevance to acquired immunity and vaccine responses.
Jordan SC
Clin Exp Immunol; 2021 Jun; 204(3):310-320. PubMed ID: 33534923
[TBL] [Abstract][Full Text] [Related]
4. Prophylactic intranasal administration of a TLR2/6 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model.
Proud PC; Tsitoura D; Watson RJ; Chua BY; Aram MJ; Bewley KR; Cavell BE; Cobb R; Dowall S; Fotheringham SA; Ho CMK; Lucas V; Ngabo D; Rayner E; Ryan KA; Slack GS; Thomas S; Wand NI; Yeates P; Demaison C; Zeng W; Holmes I; Jackson DC; Bartlett NW; Mercuri F; Carroll MW
EBioMedicine; 2021 Jan; 63():103153. PubMed ID: 33279857
[TBL] [Abstract][Full Text] [Related]
5. Upper respiratory tract mucosal immunity for SARS-CoV-2 vaccines.
Fraser R; Orta-Resendiz A; Mazein A; Dockrell DH
Trends Mol Med; 2023 Apr; 29(4):255-267. PubMed ID: 36764906
[TBL] [Abstract][Full Text] [Related]
6. Human Nasal and Lung Tissues Infected
Alfi O; Yakirevitch A; Wald O; Wandel O; Izhar U; Oiknine-Djian E; Nevo Y; Elgavish S; Dagan E; Madgar O; Feinmesser G; Pikarsky E; Bronstein M; Vorontsov O; Jonas W; Ives J; Walter J; Zakay-Rones Z; Oberbaum M; Panet A; Wolf DG
J Virol; 2021 Jun; 95(14):e0013021. PubMed ID: 33893170
[TBL] [Abstract][Full Text] [Related]
7. COVID-19 Vaccines for Optimizing Immunity in the Upper Respiratory Tract.
Ramasamy R
Viruses; 2023 Oct; 15(11):. PubMed ID: 38005881
[TBL] [Abstract][Full Text] [Related]
8. Oral Bacteria Combined with an Intranasal Vaccine Protect from Influenza A Virus and SARS-CoV-2 Infection.
Nagai M; Moriyama M; Ichinohe T
mBio; 2021 Aug; 12(4):e0159821. PubMed ID: 34399617
[TBL] [Abstract][Full Text] [Related]
9. Intranasal vaccines for SARS-CoV-2: From challenges to potential in COVID-19 management.
Chavda VP; Vora LK; Pandya AK; Patravale VB
Drug Discov Today; 2021 Nov; 26(11):2619-2636. PubMed ID: 34332100
[TBL] [Abstract][Full Text] [Related]
10. Analysis of blood and nasal epithelial transcriptomes to identify mechanisms associated with control of SARS-CoV-2 viral load in the upper respiratory tract.
Moradi Marjaneh M; Challenger JD; Salas A; Gómez-Carballa A; Sivananthan A; Rivero-Calle I; Barbeito-Castiñeiras G; Foo CY; Wu Y; Liew F; Jackson HR; Habgood-Coote D; D'Souza G; Nichols SJ; Wright VJ; Levin M; Kaforou M; Thwaites RS; Okell LC; Martinón-Torres F; Cunnington AJ; ;
J Infect; 2023 Dec; 87(6):538-550. PubMed ID: 37863321
[TBL] [Abstract][Full Text] [Related]
11. SARS-CoV-2 infection and viral load are associated with the upper respiratory tract microbiome.
Rosas-Salazar C; Kimura KS; Shilts MH; Strickland BA; Freeman MH; Wessinger BC; Gupta V; Brown HM; Rajagopala SV; Turner JH; Das SR
J Allergy Clin Immunol; 2021 Apr; 147(4):1226-1233.e2. PubMed ID: 33577896
[TBL] [Abstract][Full Text] [Related]
12. Influence of Aerosol Delivered BCG Vaccination on Immunological and Disease Parameters Following SARS-CoV-2 Challenge in Rhesus Macaques.
White AD; Sibley L; Sarfas C; Morrison AL; Bewley K; Churchward C; Fotheringham S; Gkolfinos K; Gooch K; Handley A; Humphries HE; Hunter L; Kennard C; Longet S; Mabbutt A; Moffatt M; Rayner E; Tipton T; Watson R; Hall Y; Bodman-Smith M; Gleeson F; Dennis M; Salguero FJ; Carroll M; McShane H; Cookson W; Hopkin J; Sharpe S
Front Immunol; 2021; 12():801799. PubMed ID: 35222355
[TBL] [Abstract][Full Text] [Related]
13. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
[TBL] [Abstract][Full Text] [Related]
14. Toll-like receptor-agonist-based therapies for respiratory viral diseases: thinking outside the cell.
Girkin JLN; Maltby S; Bartlett NW
Eur Respir Rev; 2022 Jun; 31(164):. PubMed ID: 35508333
[TBL] [Abstract][Full Text] [Related]
15. Nasal vaccination against SARS-CoV-2: Synergistic or alternative to intramuscular vaccines?
Tiboni M; Casettari L; Illum L
Int J Pharm; 2021 Jun; 603():120686. PubMed ID: 33964339
[TBL] [Abstract][Full Text] [Related]
16. Protection against SARS-CoV-2 infection by a mucosal vaccine in rhesus macaques.
Sui Y; Li J; Zhang R; Prabhu SK; Andersen H; Venzon D; Cook A; Brown R; Teow E; Velasco J; Greenhouse J; Putman-Taylor T; Campbell TA; Pessaint L; Moore IN; Lagenaur L; Talton J; Breed MW; Kramer J; Bock KW; Minai M; Nagata BM; Lewis MG; Wang LX; Berzofsky JA
JCI Insight; 2021 Apr; 6(10):. PubMed ID: 33908897
[TBL] [Abstract][Full Text] [Related]
17. Severe COVID-19 Is Associated With an Altered Upper Respiratory Tract Microbiome.
Shilts MH; Rosas-Salazar C; Strickland BA; Kimura KS; Asad M; Sehanobish E; Freeman MH; Wessinger BC; Gupta V; Brown HM; Boone HH; Patel V; Barbi M; Bottalico D; O'Neill M; Akbar N; Rajagopala SV; Mallal S; Phillips E; Turner JH; Jerschow E; Das SR
Front Cell Infect Microbiol; 2021; 11():781968. PubMed ID: 35141167
[TBL] [Abstract][Full Text] [Related]
18. The Upper Respiratory Tract Microbiome Network Impacted by SARS-CoV-2.
Li W; Ma ZS
Microb Ecol; 2023 Aug; 86(2):1428-1437. PubMed ID: 36509943
[TBL] [Abstract][Full Text] [Related]
19. Differential host responses within the upper respiratory tract and peripheral blood of children and adults with SARS-CoV-2 infection.
Hurst JH; Mohan AA; Dalapati T; George IA; Aquino JN; Lugo DJ; Pfeiffer TS; Rodriguez J; Rotta AT; Turner NA; Burke TW; McClain MT; Henao R; DeMarco CT; Louzao R; Denny TN; Walsh KM; Xu Z; Mejias A; Ramilo O; Woods CW; Kelly MS
medRxiv; 2023 Aug; ():. PubMed ID: 37577568
[TBL] [Abstract][Full Text] [Related]
20. Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days.
Gil-Manso S; Carbonell D; López-Fernández L; Miguens I; Alonso R; Buño I; Muñoz P; Ochando J; Pion M; Correa-Rocha R
Front Immunol; 2021; 12():726960. PubMed ID: 34671348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
